HOLLISTON, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO) (the “Company”), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, today reported its financial results for the quarter ended March 31, 2017.
Financial Results for the Quarter Ended March 31, 2017
Revenues for the three months ended March 31, 2017 were $24.2 million, a decrease of approximately 10.4%, or $2.8 million compared to revenues of $27.0 million for the three months ended March 31, 2016. Excluding currency translation, revenues decreased 8%, or $2.1 million. Included in the organic revenue decline for the quarter is a decrease in revenue of approximately $0.7 million, principally as a result of the AHN disposition in October 2016. For a reconciliation of changes in revenues, refer to Exhibit 9 below.
